Inhalation Strategy

Chronic lung rejection, Bronchiolitis Obliterans, is affecting the bronchiolar tissue. Due to the narrow therapeutic window of immunosuppressive drugs, systemic administration of Cyclosporine A does not allow for concentrations necessary to achieve effective drug doses at the target site in the bronchioles.

The method of choice to tackle BO is the delivery of aerosolized immunosuppressant via inhalation in high doses with a well-tolerated formulation to the site of action - the bronchioles.

Our data indicate significant inhalation benefit over oral delivery of Cyclosporine A.